156 related articles for article (PubMed ID: 27729767)
21. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs.
Pesic M; Markovic JZ; Jankovic D; Kanazir S; Markovic ID; Rakic L; Ruzdijic S
J Chemother; 2006 Feb; 18(1):66-73. PubMed ID: 16572896
[TBL] [Abstract][Full Text] [Related]
22. Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer.
Nakanishi Y; Kawasaki M; Bai F; Takayama K; Pei XH; Takano K; Inoue K; Osaki S; Hara N; Kiyohara C
Oncology; 1999 Nov; 57(4):318-23. PubMed ID: 10575319
[TBL] [Abstract][Full Text] [Related]
23. OTU deubiquitinase 5 inhibits the progression of non-small cell lung cancer via regulating p53 and PDCD5.
Kang XY; Zhang J; Tang L; Huang L; Tong J; Fu Q
Chem Biol Drug Des; 2020 Aug; 96(2):790-800. PubMed ID: 32248621
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells.
Kataoka M; Wiehle S; Spitz F; Schumacher G; Roth JA; Cristiano RJ
Oncogene; 2000 Mar; 19(12):1589-95. PubMed ID: 10734319
[TBL] [Abstract][Full Text] [Related]
26. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
27. Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer.
Gorzalczany Y; Gilad Y; Amihai D; Hammel I; Sagi-Eisenberg R; Merimsky O
Cancer Lett; 2011 Nov; 310(2):207-15. PubMed ID: 21807458
[TBL] [Abstract][Full Text] [Related]
28. TRIM65 negatively regulates p53 through ubiquitination.
Li Y; Ma C; Zhou T; Liu Y; Sun L; Yu Z
Biochem Biophys Res Commun; 2016 Apr; 473(1):278-282. PubMed ID: 27012201
[TBL] [Abstract][Full Text] [Related]
29. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
30. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines.
Tsai CM; Chang KT; Wu LH; Chen JY; Gazdar AF; Mitsudomi T; Chen MH; Perng RP
Cancer Res; 1996 Jan; 56(1):206-9. PubMed ID: 8548764
[TBL] [Abstract][Full Text] [Related]
31. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
[TBL] [Abstract][Full Text] [Related]
32. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648
[TBL] [Abstract][Full Text] [Related]
33. Triptolide enhances chemotherapeutic efficacy of antitumor drugs in non-small-cell lung cancer cells by inhibiting Nrf2-ARE activity.
Zhu J; Wang H; Chen F; Lv H; Xu Z; Fu J; Hou Y; Xu Y; Pi J
Toxicol Appl Pharmacol; 2018 Nov; 358():1-9. PubMed ID: 30196066
[TBL] [Abstract][Full Text] [Related]
34. Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells.
Singhal SS; Singhal J; Sharma R; Singh SV; Zimniak P; Awasthi YC; Awasthi S
Int J Oncol; 2003 Feb; 22(2):365-75. PubMed ID: 12527936
[TBL] [Abstract][Full Text] [Related]
35. Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells.
Punia R; Raina K; Agarwal R; Singh RP
PLoS One; 2017; 12(8):e0182870. PubMed ID: 28859099
[TBL] [Abstract][Full Text] [Related]
36. [P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a meta-analysis].
Wang JL; Jiao SC; Ye P; Li JY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):770-3. PubMed ID: 18504201
[TBL] [Abstract][Full Text] [Related]
37. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
Cao Z; Liang N; Yang H; Li S
Cell Prolif; 2017 Oct; 50(5):. PubMed ID: 28762597
[TBL] [Abstract][Full Text] [Related]
38. Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer.
Guo L; Zhou Y; Sun Y; Zhang F
Eur J Cancer; 2010 Feb; 46(3):636-41. PubMed ID: 20004564
[TBL] [Abstract][Full Text] [Related]
39. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
Lei W; Mayotte JE; Levitt ML
Anticancer Res; 1999; 19(1A):221-8. PubMed ID: 10226546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
